*** CHEMICAL IDENTIFICATION ***
RTECS NUMBER : BV8152500
CHEMICAL NAME : Androst-4-ene-3,17-dione, 4-hydroxy-
CAS REGISTRY NUMBER : 566-48-3
BEILSTEIN REFERENCE NO. : 1889793
LAST UPDATED : 199709
DATA ITEMS CITED : 4
MOLECULAR FORMULA : C19-H26-O3
MOLECULAR WEIGHT : 302.45
WISWESSER LINE NOTATION : L E5 B666 FV OV MUTJ A1 E1 NQ
COMPOUND DESCRIPTOR : Reproductive Effector
Hormone
SYNONYMS/TRADE NAMES :
* CGP 32349
* Formestane
* 4-Hydroxy-delta(sub 4)-androstenedione
* 4-Hydroxy-4-androstene-3,17-dione
*** HEALTH HAZARD DATA ***
** REPRODUCTIVE DATA **
TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rat
DOSE : 182 mg/kg
SEX/DURATION : female 3-5 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition
REFERENCE :
JOENAK Journal of Endocrinology. (Biochemical Soc. Book Depot, POB 32,
Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1939-
Volume(issue)/page/year: 118,93,1988
TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rat
DOSE : 136 mg/kg
SEX/DURATION : female 2-4 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects
REFERENCE :
JOENAK Journal of Endocrinology. (Biochemical Soc. Book Depot, POB 32,
Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1939-
Volume(issue)/page/year: 118,93,1988
TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Subcutaneous
SPECIES OBSERVED : Rodent - rat
DOSE : 120 mg/kg
SEX/DURATION : female 11-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - behavioral
REFERENCE :
ECJPAE Endocrinologia Japonica. (Japan Pub. Trading Co., Ltd., POB 5030,
Tokyo International, Tokyo, Japan) V.1- 1954- Volume(issue)/page/year:
36,29,1989
TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intramuscular
SPECIES OBSERVED : Rodent - rat
DOSE : 250 mg/kg
SEX/DURATION : female 3-7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in
number of implants per female; total number of implants per corpora lutea)
REFERENCE :
ENDOAO Endocrinology (Baltimore). (Williams & Wilkins Co., 428 E. Preston
St., Baltimore, MD 21203) V.1- 1917- Volume(issue)/page/year:
100,1684,1977
*** END OF RECORD ***